Literature DB >> 9429236

Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations.

H G Xie1, Z H Xu, D S Ou-Yang, Y Shu, D L Yang, J S Wang, X D Yan, S L Huang, W Wang, H H Zhou.   

Abstract

Data on both the incidence of slow acetylator phenotype of probe drugs isoniazid, sulfadimidine or sulfamethazine, caffeine and dapsone in mainland or overseas Chinese, and the distribution of NAT2 genotypes and the frequency of NAT2 alleles in the Chinese populations were summarized and reanalysed using a meta-analysis method. Frequency of the slow acetylator phenotype in 3516 healthy Han Chinese gave an overall mean of approximately 19.9 +/- 4.0%, with the range of the combined data being between 15.8% and 25.5%. In addition, frequencies of the slow acetylator phenotype differ between the different minorities in Chinese populations and the range was between 3.2% and 50.6%, with a mean value of 20.6 +/- 12.9% in a total of 1842 individuals from 17 Chinese minorities. In addition, there was no significant heterogeneity in overseas Chinese between the probe drugs isoniazid and sulfadimidine or sulfamethazine (chi 2 = 5.97, df = 4; p > 0.05), and the mean value of slow acetylator phenotype incidence was 24.5% (119/485; 95% CI: 20.7-28.3%), consistent with that of the native Chinese. As expected, frequency of the slow acetylator genotypes in Chinese populations was 25.4% (112/441; 95% CI: 21.3-29.5%), which was in accordance with that of the slow acetylator phenotype in native or overseas Chinese. For all genotypes, *4/*4 (29.9%, 132/441), *4/*6A (27.4%, 121/441), *4/*7A (12%, 53/441) and *6A/*6A (11.3%, 50/441) occupied 80.6%, but *5A/*7A (0.2%, 1/441), *5A/*5A (1.1%, 5/441) and *7A/*7A (1.8%, 8/441) were not frequently found. From this report, the genotype frequencies of homozygous rapid acetylator, heterozygous rapid acetylator, and homozygous slow acetylator were found to be 0.299 (132/441), 0.447 (197/441) and 0.254 (112/441), respectively. Furthermore, both *4 (52.3%; 95% CI: 49-56%) and *6A (30.5%; 95% CI: 28-34%) were major NAT2 alleles, while *7A (11.2%; 95% CI: 9-13%) and *5A (6%; 95% CI: 4-8%) were uncommonly present. Frequency of the mutant alleles was observed at 0.477 (421/882 alleles). The *7A constituted 23.5% t(99/421) of slow acetylator alleles in Chinese populations, showing that this point mutation exists not only in Oriental or Asiatic, but also in Chinese populations. According to the Hardy-Weinberg equilibrium, in the phenotyped Chinese populations, the mean estimate of predicted allelic frequencies of the genotypes RR, Rr, and rr was 0.294, 0.496, and 0.210 for the Chinese, and the expected frequency of the deficient gene r was 0.458. By comparison, the predicted values are in complete agreement with the observed ones. In conclusion, this meta-analysis determined the accurate population frequencies of phenotype and genotype of the NAT2 genetic deficiency in healthy Chinese subjects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429236     DOI: 10.1097/00008571-199712000-00009

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Authors:  Nicolas Vuilleumier; Michel F Rossier; Alberto Chiappe; Florence Degoumois; Pierre Dayer; Bernadette Mermillod; Laurent Nicod; Jules Desmeules; Denis Hochstrasser
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

2.  The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.

Authors:  Bing Chen; Wei-Xia Zhang; Wei-Min Cai
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

3.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

4.  Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population.

Authors:  Daya S L Srivastava; Rama D Mittal
Journal:  BMC Urol       Date:  2005-08-06       Impact factor: 2.264

Review 5.  N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction.

Authors:  J Green; E Banks; A Berrington; S Darby; H Deo; R Newton
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

6.  Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.

Authors:  Zhi-duo Hou; Zheng-yu Xiao; Yao Gong; Yu-ping Zhang; Qing Yu Zeng
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-21       Impact factor: 2.483

7.  Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.

Authors:  Jen-Jia Yang; Chung-Hao Huang; Chun-Eng Liu; Hung-Jen Tang; Chia-Jui Yang; Yi-Chien Lee; Kuan-Yeh Lee; Mao-Song Tsai; Shu-Wen Lin; Yen-Hsu Chen; Po-Liang Lu; Chien-Ching Hung
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

8.  N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.

Authors:  Prashant S Adole; Parampreet S Kharbanda; Sadhna Sharma
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

9.  Is NAT2 Gene Polymorphism Associated with Vitiligo?

Authors:  Daya Shankar Lal Srivastava; Kamal Aggarwal; Gajendra Singh
Journal:  Indian J Dermatol       Date:  2020 May-Jun       Impact factor: 1.494

10.  The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Authors:  Yang Xiang; Long Ma; Weidong Wu; Wei Liu; Yongguang Li; Xia Zhu; Qian Wang; Jinfeng Ma; Mingqin Cao; Qian Wang; Xuemei Yao; Lei Yang; Atikaimu Wubuli; Corinne Merle; Paul Milligan; Ying Mao; Jiayi Gu; Xiumei Xin
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.